PMID- 26214646
OWN - NLM
STAT- MEDLINE
DCOM- 20150825
LR  - 20151001
IS  - 1107-0625 (Print)
IS  - 1107-0625 (Linking)
VI  - 20
IP  - 3
DP  - 2015 May-Jun
TI  - Increased cancer risk associated with the -607C/A polymorphism in interleukin-18 
      gene promoter: an updated meta-analysis including 12,502 subjects.
PG  - 902-17
AB  - PURPOSE: Increasing investigations have been performed on the association of 
      -607C/A polymorphism in Interleukin-18 (IL-18) gene promoter with cancer risk and 
      have yielded conflicting results. To derive a more precise estimation of the 
      association, we performed an updated meta-analysis of all eligible studies. 
      METHODS: We searched all eligible studies by using PubMed, MEDLINE, EMBASE, and 
      China National Knowledge Infrastructure (CNKI) databases. The odds ratios (ORs) 
      were pooled by the fixed-effects/random-effects model in STATA 12.0 software. 
      RESULTS: This meta-analysis included 29 studies with 6,026 cases and 6,476 
      controls. Overall, significantly increased cancer risk was observed (A vs C: 
      OR=1.10, 95% CI: 1.01,1.19, Pheterogeneity=0.001; AA vs CC: OR=1.17, 95% CI: 
      1.01,1.37, Pheterogeneity=0.007; CA vs CC: OR=1.15, 95% CI: 1.05,1.25, 
      Pheterogeneity=0.152; AA/CA vs CC: OR=1.17, 95% CI: 1.06,1.31, 
      Pheterogeneity=0.042). In subgroup analyses based on ethnicity, the results 
      suggested a significantly increased risk of cancer in Asian population (CA vs CC: 
      OR=1.11, 95% CI: 1.00-1.24, Pheterogeneity=0.353; AA/CA vs CC: OR=1.14, 95% CI: 
      1.02-1.29, Pheterogeneity=0.081) and in Mixed population (A vs C: OR=1.72, 95% 
      CI: 1.22-2.43, Pheterogeneity=NA; AA vs CC: OR=2.84, 95% CI: 1.43-5.64, 
      Pheterogeneity=NA; AA vs CC/CA: OR=2.43, 95% CI: 1.34-4.42, Pheterogeneity=NA; 
      AA/CA vs CC: OR=1.69, 95% CI: 1.00-2.85, Pheterogeneity=NA); however, no 
      significant association was found in Caucasian or African populations. In the 
      subgroup analysis by cancer type we found a significantly increased 
      susceptibility to breast cancer (A vs C: OR=1.33, 95% CI: 
      1.00-1.75,Pheterogeneity=0.155; AA vs CC: OR=1.80, 95% CI: 
      1.02-3.21,Pheterogeneity=0.162; AA7sol;CA vs CC: OR=1.33, 95% CI: 
      1.00-1.78,Pheterogeneity=0.546), nasopharyngeal carcinoma (A vs C: OR=1.16, 95% 
      CI: 1.01-1.32, Pheterogeneity=0.921; AA vs CC: OR=1.34, 95% CI: 1.02-1.75, 
      Pheterogeneity=0.863; CA vs. CC: OR=1.36, 95% CI: 1.08-1.70, 
      Pheterogeneity=0.824; AA/CA vs CC: OR=1.35, 95% CI: 
      1.09-1.68,Pheterogeneity=0.904), and esophageal cancer (CA vs CC: OR=1.37, 95% 
      CI: 1.04-1.80, Pheterogeneity=0.528; AA/CA vs CC: OR =1.29, 95% CI: 1.00-1.66, 
      Pheterogeneity=0.700). CONCLUSIONS: The current meta-analysis suggests that the 
      -607C/A polymorphism in IL-18 gene promoter is associated with a significantly 
      increased risk of cancer, especially of breast cancer, nasopharyngeal carcinoma 
      and esophageal cancer and in Asian and Mixed populations. More studies with 
      diverse ethnic groups, larger sample size, and well controlled confounding 
      factors are warranted to further investigate the association.
FAU - Li, Xiangnan
AU  - Li X
AD  - Department of General Surgery, Dalian Medical University, Liaoning Province, 
      China.
FAU - Ren, Dongliang
AU  - Ren D
FAU - Li, Yanyan
AU  - Li Y
FAU - Xu, Jingchao
AU  - Xu J
FAU - Liu, Chen
AU  - Liu C
FAU - Zhao, Yongfu
AU  - Zhao Y
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PL  - Cyprus
TA  - J BUON
JT  - Journal of B.U.ON. : official journal of the Balkan Union of Oncology
JID - 100883428
RN  - 0 (Interleukin-18)
SB  - IM
MH  - Case-Control Studies
MH  - Gene Frequency
MH  - Genetic Association Studies
MH  - Genetic Predisposition to Disease
MH  - Humans
MH  - Interleukin-18/*genetics
MH  - Neoplasms/diagnosis/ethnology/*genetics/immunology
MH  - Odds Ratio
MH  - Phenotype
MH  - *Polymorphism, Genetic
MH  - *Promoter Regions, Genetic
MH  - Risk Assessment
MH  - Risk Factors
EDAT- 2015/07/28 06:00
MHDA- 2015/08/26 06:00
CRDT- 2015/07/28 06:00
PHST- 2015/07/28 06:00 [entrez]
PHST- 2015/07/28 06:00 [pubmed]
PHST- 2015/08/26 06:00 [medline]
PST - ppublish
SO  - J BUON. 2015 May-Jun;20(3):902-17.